Literature DB >> 21621084

Testosterone deficiency and risk factors in the metabolic syndrome: implications for erectile dysfunction.

Andre T Guay1, Abdulmaged Traish.   

Abstract

The most common cause of erectile dysfunction (ED) is penile vascular insufficiency. This is usually part of a generalized endothelial dysfunction and is related to several conditions, including type 2 diabetes mellitus, hypertension, hyperlipidemia, and obesity. These conditions underlie the pathophysiology of metabolic syndrome (MetS). Hypogonadism, or testosterone deficiency (TD), is an integral component of the pathology underlying endothelial dysfunction and MetS, with insulin resistance (IR) at its core. Testosterone replacement therapy for TD has been shown to ameliorate some of the components of the MetS, improve IR, and may serve as treatment for decreasing cardiovascular and ED risk. 2011 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21621084     DOI: 10.1016/j.ucl.2011.02.004

Source DB:  PubMed          Journal:  Urol Clin North Am        ISSN: 0094-0143            Impact factor:   2.241


  8 in total

Review 1.  Peptides in seminal fluid and their role in infertility: a potential role for opiorphin inhibition of neutral endopeptidase activity as a clinically relevant modulator of sperm motility: a review.

Authors:  Jayme S Bosler; Kelvin P Davies; Genevieve S Neal-Perry
Journal:  Reprod Sci       Date:  2014-05-22       Impact factor: 3.060

2.  A survey on relative frequency of metabolic syndrome and testosterone deficiency in men with erectile dysfunction.

Authors:  Ali Hamidi Madani; Abtin Heidarzadeh; Niloofar Akbari Parsa; Fatemeh Khosravi Darestani; Zahra Hamidi Madani
Journal:  Int Urol Nephrol       Date:  2011-11-25       Impact factor: 2.370

Review 3.  Molecular mechanisms associated with diabetic endothelial-erectile dysfunction.

Authors:  Ângela Castela; Carla Costa
Journal:  Nat Rev Urol       Date:  2016-02-16       Impact factor: 14.432

Review 4.  Testosterone supplementation therapy in the treatment of patients with metabolic syndrome.

Authors:  Jason R Kovac; Jason Kovac; Alexander W Pastuszak; Dolores J Lamb; Larry I Lipshultz
Journal:  Postgrad Med       Date:  2014-11       Impact factor: 3.840

5.  Testosterone Levels Are Not Associated With Magnitude of Deformity in Men With Peyronie's Disease.

Authors:  John P Mulhall; Kazuhito Matsushita; Christian J Nelson
Journal:  J Sex Med       Date:  2019-07-11       Impact factor: 3.802

6.  Diagnostic value of four-dimensional CT angiography in arterial erectile dysfunction using 320-detector row dynamic volume CT.

Authors:  Cheng-Cheng Xu; Xin-Zhong Ruan; Yi-Fan Tang; Jiao-Hai Pan; Guo-Yao Wang; Qiu-Li Huang
Journal:  Biosci Rep       Date:  2017-08-21       Impact factor: 3.840

7.  Do we have enough evidences that make you safe to treat a man with hypogonadism one year after a radical prostatectomy for prostate cancer? | Opinion: Not Yet.

Authors:  Marcelo Langer Wroclawski; Flavio Lobo Heldwein
Journal:  Int Braz J Urol       Date:  2018 Jan-Feb       Impact factor: 1.541

Review 8.  Diagnosis and management of testosterone deficiency.

Authors:  James A McBride; Culley C Carson; Robert M Coward
Journal:  Asian J Androl       Date:  2015 Mar-Apr       Impact factor: 3.285

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.